Acumen Pharmaceuticals, Inc. (ABOS)
NasdaqGS · USD · Healthcare · Biotechnology
$2.23 (-1.98%) as of
Key statistics
- Market cap
- 160.93M
- Forward P/E
- -1.47
- EPS (TTM)
- -1.8800
- Dividend yield
- 0.00%
- 52-week range
- 1.5000 – 3.6000
- Beta
- 0.33
- Profit margin
- 0.00%
- Analyst target
- $7.60
- Volume
- 619.22k
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Newton, MA, United States
- Employees
- 60
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.